The Diabetes Prevention Program and the Metabolic Syndrome
Authors: Frank A. Anania, Samir Parekh, Aasma Shaukat
Journal: Annals of Internal Medicine (2005)

Letters4 October 2005The Diabetes Prevention Program and the Metabolic SyndromeFrank A. Anania, MD, Samir Parekh, MD, and Aasma Shaukat, MDFrank A. Anania, MDFrom Emory University School of Medicine, Atlanta, GA 30322.Search for more papers by this author, Samir Parekh, MDFrom Emory University School of Medicine, Atlanta, GA 30322.Search for more papers by this author, and Aasma Shaukat, MDFrom Emory University School of Medicine, Atlanta, GA 30322.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-143-7-200510040-00022 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:The most recent results published by Orchard and colleagues (1) in association with the Diabetes Prevention Program failed to present the patients' serum alanine aminotransferase (ALT) values at study entry and at completion of pharmacologic intervention with metformin or the intensive lifestyle modifications tested. Nonalcoholic fatty liver disease is now the most common reason that patients are referred to a gastroenterologist for abnormal results on liver function tests (2). Results from the National Health and Nutrition Examination Survey III database also suggest that up to 28% of patients have nonalcoholic fatty liver disease, and there is a ...References1. Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med. 2005;142:611-9. [PMID: 15838067] LinkGoogle Scholar2. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology. 2003;37:1202-19. [PMID: 12717402] CrossrefMedlineGoogle Scholar3. Yu AS, Keeffe EB. Nonalcoholic fatty liver disease. Rev Gastroenterol Disord. 2002;2:11-9. [PMID: 12122975] MedlineGoogle Scholar4. Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med. 2000;6:998-1003. [PMID: 10973319] CrossrefMedlineGoogle Scholar5. Nair S, Diehl AM, Wiseman M, Farr GH, Perrillo RP. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther. 2004;20:23-8. [PMID: 15225167] CrossrefMedlineGoogle Scholar6. Jadhao SB, Yang RZ, Lin Q, Hu H, Anania FA, Shuldiner AR, et al. Murine alanine aminotransferase: cDNA cloning, functional expression, and differential gene regulation in mouse fatty liver. Hepatology. 2004;39:1297-302. [PMID: 15122758] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Emory University School of Medicine, Atlanta, GA 30322.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoThe Effect of Metformin and Intensive Lifestyle Intervention on the Metabolic Syndrome: The Diabetes Prevention Program Randomized Trial Trevor J. Orchard , Marinella Temprosa , Ronald Goldberg , Steven Haffner , Robert Ratner , Santica Marcovina , Sarah Fowler , and The Diabetes Prevention Program and the Metabolic Syndrome Trevor J. Orchard , Marinella Temprosa , and Robert Ratner The Diabetes Prevention Program and the Metabolic Syndrome Priscilla S. Sarinas and Daniel S. Dube Metrics 4 October 2005Volume 143, Issue 7Page: 545KeywordsChronic liver diseaseDiabetes preventionFatty liverGlucose intoleranceHealth surveysInsulin resistanceMetabolic syndromeNon-alcoholic fatty liver diseaseObesity ePublished: 4 October 2005 Issue Published: 4 October 2005 CopyrightCopyright © 2005 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...